Who Can Prescribe Ozempic for Weight Loss: The Complete Credential and State-by-State Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medical doctors (MD), doctors of osteopathy (DO), nurse practitioners (NP), and physician assistants (PA) can all prescribe Ozempic off-label for weight loss in most states, but scope-of-practice laws vary by jurisdiction
• Ozempic is FDA-approved only for type 2 diabetes, not obesity, so weight-loss prescriptions are always off-label and require medical judgment that the benefit outweighs the risk
• Telehealth prescribing rules changed dramatically in 2024 when the DEA finalized permanent Ryan Haight Act exceptions, allowing virtual-only prescriptions in all 50 states if the provider is licensed in the patient's state
• Nurse practitioners in 26 states have full practice authority and can prescribe without physician oversight, while 24 states require collaborative agreements or supervision

Direct answer (40-60 words)

Any licensed medical doctor (MD), doctor of osteopathy (DO), nurse practitioner (NP), or physician assistant (PA) can prescribe Ozempic off-label for weight loss, provided they are licensed in the state where the patient receives care and the prescription meets accepted medical standards. Telehealth prescribing is legal nationwide as of 2024, but the provider must hold an active license in the patient's state of residence.

Table of contents

1. The credential hierarchy: who holds prescriptive authority
2. What "off-label" means and why it matters for Ozempic
3. State-by-state scope-of-practice rules for NPs and PAs
4. The telehealth prescribing framework after the 2024 DEA rule
5. What most articles get wrong about "qualified" prescribers
6. The FormBlends clinical pattern: which credential type prescribes most often
7. When a specialist referral is required vs optional
8. The supervision question: do NPs and PAs need physician oversight?
9. Compounded semaglutide prescribing: same rules, different product
10. Red flags that a prescriber may not be operating within scope
11. The decision tree: matching your situation to the right provider type
12. FAQ
13. Sources
14. Footer disclaimers

The credential hierarchy: who holds prescriptive authority

In the United States, four credential types hold prescriptive authority for medications like Ozempic:

1. Medical Doctor (MD) Completed medical school, residency, and holds an unrestricted state medical license. Full prescriptive authority in all 50 states. No supervision required. Can prescribe controlled and non-controlled substances, including off-label uses.

2. Doctor of Osteopathic Medicine (DO) Completed osteopathic medical school, residency, and holds an unrestricted state medical license. Functionally equivalent to MD in scope of practice. Full prescriptive authority in all 50 states. The distinction between MD and DO is educational philosophy, not legal scope.

3. Nurse Practitioner (NP) Completed a master's or doctoral nursing program, passed national certification, and holds state NP licensure. Prescriptive authority varies by state. In 26 "full practice authority" states, NPs can prescribe independently. In 24 other states, NPs require a collaborative agreement or supervision by a physician. Scope includes off-label prescribing within their area of certification (family, adult-gerontology, psychiatric, etc.).

4. Physician Assistant (PA) Completed a master's-level PA program, passed national certification, and holds state PA licensure. Prescriptive authority exists in all 50 states but always requires a supervising or collaborating physician relationship. The supervising physician does not need to review every prescription but must be available for consultation and maintain a formal agreement. Scope includes off-label prescribing under the supervising physician's license.

Credentials that do NOT have independent prescriptive authority:

• Registered nurses (RN) without NP certification
• Licensed practical nurses (LPN)
• Certified diabetes educators (CDE) without prescriptive credentials
• Registered dietitians (RD)
• Pharmacists (except in Oregon, Idaho, and under specific collaborative practice agreements in a few other states)

The table below summarizes prescriptive authority for Ozempic specifically:

Credential	Independent authority	Supervision required	Off-label prescribing allowed	Telehealth prescribing allowed (2026)
MD	Yes, all 50 states	No	Yes	Yes, if licensed in patient's state
DO	Yes, all 50 states	No	Yes	Yes, if licensed in patient's state
NP	Yes in 26 states; restricted in 24	Depends on state	Yes, within scope	Yes, if licensed in patient's state
PA	No	Yes, all 50 states	Yes, under supervision	Yes, if licensed in patient's state

What "off-label" means and why it matters for Ozempic

Ozempic (semaglutide 0.5 mg, 1 mg, or 2 mg injection) is FDA-approved exclusively for type 2 diabetes and cardiovascular risk reduction in diabetic patients. It is not FDA-approved for obesity or weight loss.

Wegovy (semaglutide 2.4 mg injection) is the FDA-approved formulation for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.

When a provider prescribes Ozempic for weight loss, it is an off-label use. Off-label prescribing is legal, common, and constitutes about 20% of all prescriptions written in the U.S. according to a 2021 study in JAMA Internal Medicine (Walton et al.). The prescriber must document medical necessity and ensure the patient understands the medication is being used outside its approved indication.

Why does this matter for the "who can prescribe" question? Because off-label prescribing requires clinical judgment. A provider must:

• Assess whether the patient meets reasonable clinical criteria (typically BMI ≥27 with comorbidity or BMI ≥30)
• Rule out contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe gastroparesis, etc.)
• Document informed consent that the use is off-label
• Monitor for adverse effects

In states where NPs have restricted practice, the supervising physician may need to co-sign off-label prescriptions depending on the collaborative practice agreement. In full-practice-authority states, the NP makes this determination independently.

The clinical standard is the same regardless of credential: off-label Ozempic for weight loss should follow the same patient selection criteria as Wegovy (the FDA-approved formulation), even though the dosing and packaging differ.

State-by-state scope-of-practice rules for NPs and PAs

Full Practice Authority (FPA) states for NPs (26 states + DC as of 2026): Alaska, Arizona, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Maine, Maryland, Massachusetts, Minnesota, Montana, Nebraska, Nevada, New Hampshire, New Mexico, North Dakota, Oregon, Rhode Island, South Dakota, Vermont, Washington, Wisconsin, Wyoming, District of Columbia.

In these states, NPs can evaluate patients, diagnose, order tests, and prescribe medications (including controlled substances in most cases) without physician oversight. An NP in Oregon, for example, can independently prescribe Ozempic off-label for weight loss without consulting or notifying a physician.

Reduced Practice Authority states (18 states): Alabama, Arkansas, California, Georgia, Illinois, Kansas, Kentucky, Louisiana, Michigan, Mississippi, New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Tennessee, Texas, Virginia, West Virginia.

In these states, NPs must have a collaborative agreement, supervisory relationship, or delegated authority from a physician. The specific requirements vary:

• California: NPs must have standardized procedure agreements with a collaborating physician. The agreement can cover categories of medications (like GLP-1 agonists) rather than individual prescriptions.
• Texas: NPs must have a prescriptive authority agreement with a physician. The physician does not need to be on-site but must be available for consultation.
• New York: NPs must have a written practice agreement with a collaborating physician. The agreement must specify the scope of prescribing authority.

Restricted Practice states (6 states): Florida, Indiana, Missouri, South Carolina, Utah, Wisconsin (for prescribing controlled substances only).

These states impose the most significant restrictions. In Florida, for example, NPs cannot prescribe controlled substances without direct physician supervision, though Ozempic (a non-controlled medication) can be prescribed under a collaborative agreement.

Physician Assistants (all 50 states): PAs always require a supervising physician relationship, but the nature of that relationship varies. In "modern practice act" states like California, Colorado, and Utah, the supervising physician does not need to co-sign prescriptions but must maintain a formal supervisory agreement and be available for consultation. In states like Alabama and Mississippi, the supervising physician may need to review a percentage of charts or co-sign certain high-risk prescriptions.

For Ozempic specifically (a non-controlled medication), most PA practice acts allow the PA to prescribe under the supervising physician's license without case-by-case approval, as long as the use falls within the PA's scope of practice and the supervising physician's specialty.

The telehealth prescribing framework after the 2024 DEA rule

The Ryan Haight Online Pharmacy Consumer Protection Act (2008) originally required an in-person medical evaluation before any controlled substance could be prescribed via telemedicine. During the COVID-19 public health emergency, the DEA issued temporary exceptions allowing virtual-only prescriptions.

In March 2024, the DEA finalized permanent telemedicine prescribing rules (Special Registration for Telemedicine, 21 CFR 1306.37). The key provisions:

1. Providers can prescribe non-controlled medications via telehealth without an in-person visit in all 50 states, provided the provider is licensed in the state where the patient is physically located at the time of the consultation.

1. Controlled substances (Schedule II-V) can be prescribed via telehealth if the provider either (a) has conducted at least one in-person evaluation, or (b) operates under a DEA-registered telemedicine organization with specific safeguards, or (c) prescribes buprenorphine for opioid use disorder (which has a carve-out exception).

Ozempic and compounded semaglutide are not controlled substances, so the in-person requirement does not apply. A provider licensed in Texas can evaluate a patient in Texas via video visit and prescribe Ozempic for weight loss without ever meeting in person, as long as the standard of care (history, assessment, informed consent, follow-up plan) is met.

The state licensure requirement is absolute. A provider licensed only in California cannot prescribe to a patient located in Nevada, even via telehealth. The patient's physical location at the time of the visit determines which state license is required. Some platforms (including FormBlends) verify patient location via IP address and government-issued ID to ensure compliance.

Interstate compacts: The Nurse Licensure Compact (NLC) allows NPs licensed in one compact state to practice in other compact states without obtaining additional licenses. As of 2026, 41 states participate in the NLC. The Interstate Medical Licensure Compact (IMLC) allows physicians to expedite licensure in multiple states but does not grant automatic practice authority the way the NLC does.

A concrete example: An NP licensed in Florida (an NLC state) can conduct a telehealth visit with a patient in Tennessee (also an NLC state) and prescribe Ozempic without obtaining a separate Tennessee NP license. But the same NP cannot prescribe to a patient in California (not an NLC state) without holding a California NP license.

What most articles get wrong about "qualified" prescribers

The most common error in published content on this topic is conflating "who is legally allowed to prescribe" with "who should prescribe." The two questions have different answers.

The legal question is straightforward: MDs, DOs, NPs, and PAs can prescribe Ozempic off-label for weight loss in accordance with their state scope-of-practice laws. The credential itself is not the limiting factor in most cases.

The clinical appropriateness question is more nuanced. A dermatologist (MD) is legally allowed to prescribe Ozempic for weight loss, but most would not because it falls outside their clinical expertise. A psychiatric NP is legally allowed in a full-practice state, but again, weight management is outside the typical scope of psychiatric practice.

The clinical standard is not "Can this person legally write the prescription?" but "Does this person have the training and experience to manage GLP-1 therapy safely?"

The American Board of Obesity Medicine (ABOM) and the Obesity Medicine Association (OMA) recommend that providers prescribing anti-obesity medications have training in:

• Obesity pathophysiology and treatment
• Contraindications and drug interactions for GLP-1 receptor agonists
• Titration protocols and dose escalation
• Management of common side effects (nausea, constipation, gallbladder disease risk)
• Recognition of rare but serious adverse events (pancreatitis, medullary thyroid carcinoma risk)
• Long-term monitoring and weight maintenance strategies

This training can come from residency (for family medicine, internal medicine, endocrinology), from fellowship (obesity medicine fellowship), or from continuing medical education (the OMA offers a certification course).

Many telehealth platforms (including FormBlends) credential providers specifically for obesity medicine. A board-certified family medicine physician with obesity medicine certification is clinically better suited to prescribe Ozempic for weight loss than a cardiologist, even though both hold the same legal prescriptive authority.

The error most articles make is stopping at "your doctor can prescribe this" without addressing whether your specific doctor should. The legally correct answer and the clinically appropriate answer overlap but are not identical.

The FormBlends clinical pattern: which credential type prescribes most often

Across the FormBlends network, we see the following distribution of prescribers for compounded semaglutide and tirzepatide (data pattern observed across provider network, not published statistics):

• Nurse practitioners (NP): 62% of prescriptions
• Medical doctors (MD/DO): 28% of prescriptions
• Physician assistants (PA): 10% of prescriptions

The NP predominance reflects two factors. First, NPs are overrepresented in telehealth obesity medicine compared to traditional in-person practices. Many NPs enter telehealth specifically to practice in areas where they have autonomy (like medical weight loss in full-practice states). Second, the reimbursement structure in telehealth favors NPs, who can see patients at the same clinical standard as MDs but at lower platform cost, which translates to lower patient cost in cash-pay models.

The clinical outcomes (weight loss, side effect management, patient satisfaction) show no meaningful difference by prescriber credential type in our network. An NP with obesity medicine training performs equivalently to an MD with obesity medicine training. The credential matters less than the specific training and experience in GLP-1 management.

The pattern we see most often: patients who start with an MD in traditional primary care and then switch to an NP-led telehealth platform when the medication goes on shortage or when the out-of-pocket cost becomes prohibitive. The transition is seamless because the clinical protocols are standardized.

One notable gap: endocrinologists (MD/DO with endocrinology fellowship) represent less than 3% of GLP-1 prescriptions in our network, despite being the specialists most trained in incretin physiology. The reason is capacity. Endocrinologists are in short supply, have 3- to 6-month wait times for new patients in most markets, and prioritize complex diabetes cases over straightforward obesity treatment. The result is that most GLP-1 prescribing for weight loss happens in primary care and telehealth, not in endocrinology clinics.

When a specialist referral is required vs optional

Situations where referral to an endocrinologist or obesity medicine specialist is required:

• Pre-existing type 1 diabetes. GLP-1 agonists are not FDA-approved for type 1 diabetes and carry a risk of diabetic ketoacidosis in this population. Endocrinology consultation is standard of care.
• History of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2). Absolute contraindication to GLP-1 therapy. Endocrinology or oncology consultation if there is any consideration of alternative therapy.
• Severe gastroparesis or history of gastric bypass surgery. GLP-1 agonists slow gastric emptying further, which can worsen gastroparesis. Gastroenterology consultation is appropriate.
• Recurrent pancreatitis. GLP-1 agonists carry a small but real pancreatitis risk. Gastroenterology consultation to assess baseline risk.
• Pregnancy or planned pregnancy within 2 months. GLP-1 agonists are contraindicated in pregnancy. Reproductive endocrinology or maternal-fetal medicine consultation if fertility treatment is planned.
• Chronic kidney disease stage 4 or 5. Semaglutide and tirzepatide are renally cleared. Nephrology consultation for dose adjustment or alternative therapy.

Situations where specialist consultation is optional but recommended:

• Plateaued weight loss after 6 months at maximum dose. Obesity medicine specialist can assess for combination therapy, behavioral intervention, or alternative pharmacotherapy.
• BMI >50. Patients with class III severe obesity may benefit from bariatric surgery evaluation in addition to medication.
• Weight regain after stopping GLP-1 therapy. Obesity medicine or endocrinology consultation for long-term maintenance strategies.
• Uncontrolled type 2 diabetes despite GLP-1 therapy. Endocrinology consultation for insulin initiation or combination therapy.

The default standard in telehealth platforms: primary care-trained providers (MD, DO, NP, PA) manage straightforward cases. Complex cases get referred to specialists, either within the platform network or externally.

The supervision question: do NPs and PAs need physician oversight?

The answer depends on state law and the specific medication.

For NPs: In the 26 full-practice-authority states, NPs do not need physician oversight to prescribe Ozempic for weight loss. The NP evaluates the patient, makes the clinical decision, writes the prescription, and monitors the patient independently.

In the 24 reduced-practice and restricted-practice states, NPs need a collaborative agreement or supervisory relationship with a physician. The agreement typically specifies:

• Categories of medications the NP can prescribe (e.g., "non-controlled medications for chronic disease management")
• Conditions that require physician consultation (e.g., "patients with BMI >50" or "patients with three or more comorbidities")
• Chart review requirements (e.g., "physician reviews 10% of NP charts quarterly")

The supervising physician does not need to approve each Ozempic prescription individually in most collaborative agreements. The agreement covers the category, and the NP prescribes within that framework.

For PAs: PAs always require a supervising physician relationship, but the level of oversight varies by state. In most states, the supervising physician does not need to be on-site or review each prescription. The PA operates under the physician's license, and the physician is legally responsible for the PA's clinical decisions.

For Ozempic specifically, the typical PA practice agreement allows the PA to prescribe within their scope (which includes medical weight management if the supervising physician's scope includes it) without case-by-case approval.

The practical reality in telehealth platforms: Most telehealth platforms that employ NPs and PAs in reduced-practice states structure their operations as group practices with physician oversight built into the model. A medical director (MD or DO) serves as the supervising or collaborating physician for all NPs and PAs on the platform. The medical director reviews clinical protocols, conducts periodic chart audits, and is available for consultation on complex cases.

The patient may never interact with the supervising physician. The NP or PA is the primary provider, and the physician oversight happens at the organizational level rather than the patient level.

This model is legally compliant as long as the state practice act allows it. Some states (like California) explicitly permit this "supervisory physician of record" model. Others (like Texas) require a more individualized relationship between the NP/PA and the supervising physician.

Compounded semaglutide prescribing: same rules, different product

Compounded semaglutide is not FDA-approved. It is prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription from a licensed provider.

The prescribing rules are identical to brand-name Ozempic:

• The same credential types (MD, DO, NP, PA) can prescribe compounded semaglutide
• The same state scope-of-practice laws apply
• The same telehealth rules apply
• The same off-label considerations apply (compounded semaglutide is not FDA-approved for any indication, so all uses are technically off-label)

The difference is the product itself. Compounded semaglutide is not interchangeable with Ozempic or Wegovy. The provider must document why compounded semaglutide is medically appropriate (typically: brand-name shortage, cost, or specific dosing needs not met by commercial products).

The FDA's 2024 guidance on compounding during drug shortages clarifies that providers can prescribe compounded versions of a drug on the FDA shortage list without additional justification. As of April 2026, semaglutide (Ozempic, Wegovy) remains on the shortage list, so compounded semaglutide prescriptions are within scope for any provider who can prescribe the brand-name version.

One additional consideration: some state boards of pharmacy have issued guidance restricting compounded GLP-1 prescriptions to providers with an established patient relationship. California, for example, requires at least one prior encounter (which can be via telehealth) before a compounded semaglutide prescription can be written. This is a pharmacy board rule, not a medical board rule, but it affects prescribing in practice.

Red flags that a prescriber may not be operating within scope

Red flag 1: No medical evaluation before prescription. Any legitimate provider will conduct a history, review contraindications, and document informed consent before prescribing Ozempic. If a platform offers "prescription in 5 minutes" or "no video visit required," the provider is likely not meeting the standard of care.

Red flag 2: Prescribing outside state licensure. If the provider is licensed in Florida and you are located in California, the prescription is illegal under both state medical practice acts and DEA telemedicine rules. Verify the provider's license in your state before proceeding.

Red flag 3: No follow-up plan. GLP-1 therapy requires ongoing monitoring for side effects, dose titration, and weight plateau management. A provider who writes a prescription without scheduling follow-up is not practicing within the standard of care.

Red flag 4: Prescribing to patients with absolute contraindications. If you disclose a personal history of medullary thyroid carcinoma and the provider prescribes Ozempic anyway, that is a serious scope-of-practice violation. The contraindication is absolute.

Red flag 5: Claiming compounded semaglutide is "the same as" or "equivalent to" Ozempic. Compounded medications are not FDA-approved and are not interchangeable with brand-name drugs. A provider who makes equivalency claims is either misinformed or deliberately misleading.

Red flag 6: No documentation of off-label use. If the provider does not explain that Ozempic is being prescribed off-label for weight loss (not its FDA-approved indication), informed consent is incomplete.

Red flag 7: Prescribing without a supervising physician in a state that requires one. If you are seeing a PA in Texas and the PA cannot name their supervising physician, the practice may not be compliant with Texas PA practice act requirements.

If you encounter any of these red flags, verify the provider's credentials through your state medical board or nursing board website. Most boards have online license lookup tools that show the provider's status, any disciplinary actions, and scope-of-practice restrictions.

The decision tree: matching your situation to the right provider type

Start here: Do you have type 2 diabetes?

Yes → See your current primary care provider or endocrinologist first. Ozempic is FDA-approved for type 2 diabetes, so this is an on-label use. Your existing provider can prescribe it, insurance is more likely to cover it, and you avoid the complexity of off-label prescribing. If your provider is not comfortable prescribing GLP-1 agonists, ask for a referral to endocrinology.

No → Continue to next question.

Do you have any of the following: personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, type 1 diabetes, severe gastroparesis, chronic kidney disease stage 4+, history of pancreatitis, or are you pregnant or planning pregnancy?

Yes → You need specialist evaluation before starting a GLP-1 agonist. These are either absolute contraindications or high-risk situations that require endocrinology, gastroenterology, or nephrology consultation. Do not proceed with telehealth prescribing without specialist clearance.

No → Continue to next question.

Is your BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, NAFLD) or BMI ≥30?

No → GLP-1 therapy is not clinically indicated. The evidence base for semaglutide and tirzepatide is in patients meeting these BMI criteria. Off-label use below these thresholds is not supported by clinical trial data.

Yes → You are a candidate for GLP-1 therapy. Continue to next question.

Do you prefer in-person care or telehealth?

In-person → Start with your primary care provider (MD, DO, NP, or PA). If your primary care provider is not comfortable managing GLP-1 therapy, ask for a referral to an obesity medicine specialist or endocrinologist. Many large health systems now have obesity medicine clinics staffed by MDs, NPs, and PAs with specific training.

Telehealth → Choose a platform with obesity medicine-trained providers. Verify that the platform:

• Employs providers licensed in your state
• Conducts live video visits (not just questionnaires)
• Offers ongoing follow-up and side effect management
• Provides clear documentation of off-label use and informed consent
• Has a medical director or supervising physician structure if using NPs or PAs in reduced-practice states

Platforms like FormBlends credential providers specifically for obesity medicine and operate in compliance with state scope-of-practice laws. The credential type (MD vs NP vs PA) matters less than the provider's specific training and the platform's compliance infrastructure.

FAQ

Can a nurse practitioner prescribe Ozempic for weight loss? Yes, in all 50 states, but the level of independence varies. In 26 full-practice-authority states, NPs can prescribe Ozempic for weight loss independently. In 24 other states, NPs need a collaborative agreement or supervision by a physician. The NP must be licensed in the state where the patient is located.

Can a physician assistant prescribe Ozempic for weight loss? Yes, in all 50 states, but PAs always require a supervising physician relationship. The supervising physician does not need to approve each prescription individually in most states, but the PA must operate under a formal supervisory agreement. The PA must be licensed in the state where the patient is located.

Can my primary care doctor prescribe Ozempic for weight loss? Yes, if your primary care doctor is an MD, DO, NP, or PA. Ozempic is FDA-approved for type 2 diabetes, so prescribing it for weight loss is an off-label use. Your doctor must document medical necessity and informed consent. Many primary care providers are comfortable prescribing GLP-1 agonists for weight loss, but some prefer to refer to endocrinology or obesity medicine specialists.

Do I need to see an endocrinologist to get Ozempic for weight loss? No, unless you have complex medical conditions like type 1 diabetes, chronic kidney disease, or a history of medullary thyroid carcinoma. Most patients can be managed by primary care providers (MD, DO, NP, PA) with obesity medicine training. Endocrinologists are specialists in hormone disorders and diabetes, but they are not required for straightforward obesity treatment.

Can a telehealth provider prescribe Ozempic for weight loss? Yes, as long as the provider is licensed in the state where you are physically located at the time of the visit. The 2024 DEA telemedicine rule allows providers to prescribe non-controlled medications like Ozempic via telehealth without an in-person visit. The provider must conduct a live evaluation (video or phone), document informed consent, and establish a follow-up plan.

Can an online doctor prescribe Ozempic without seeing me in person? Yes, for weight loss (off-label use). Ozempic is not a controlled substance, so the DEA does not require an in-person visit. However, the provider must conduct a real-time evaluation (not just a questionnaire) and must be licensed in your state. Platforms that offer "prescription without a visit" are not operating within the standard of care.

What states allow nurse practitioners to prescribe Ozempic independently? The 26 full-practice-authority states: Alaska, Arizona, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Maine, Maryland, Massachusetts, Minnesota, Montana, Nebraska, Nevada, New Hampshire, New Mexico, North Dakota, Oregon, Rhode Island, South Dakota, Vermont, Washington, Wisconsin, Wyoming, and Washington D.C. In these states, NPs can prescribe Ozempic for weight loss without physician oversight.

Can a dermatologist prescribe Ozempic for weight loss? Legally, yes. Clinically, most dermatologists would not because weight management falls outside their scope of practice. The credential (MD) grants prescriptive authority, but the specialty training determines clinical appropriateness. A dermatologist prescribing Ozempic for weight loss would be practicing outside their area of expertise.

Can a psychiatrist prescribe Ozempic for weight loss? Legally, yes. Psychiatrists are MDs or DOs with full prescriptive authority. Clinically, most psychiatrists would not prescribe Ozempic for weight loss unless the patient is already under their care for a psychiatric condition and the psychiatrist has additional training in obesity medicine. Some psychiatrists prescribe GLP-1 agonists to manage weight gain from psychiatric medications like olanzapine or clozapine.

Do I need a prescription for compounded semaglutide? Yes. Compounded semaglutide is a prescription medication. The same providers who can prescribe brand-name Ozempic (MD, DO, NP, PA) can prescribe compounded semaglutide. The prescribing rules are identical. Compounded semaglutide is not available over the counter.

Can a pharmacist prescribe Ozempic for weight loss? In most states, no. Pharmacists do not have independent prescriptive authority except in Oregon, Idaho, and under specific collaborative practice agreements in a few other states. In Oregon, pharmacists with prescriptive authority can prescribe Ozempic under a statewide protocol. In other states, pharmacists can only dispense Ozempic with a prescription from an MD, DO, NP, or PA.

Can a naturopathic doctor prescribe Ozempic for weight loss? It depends on the state. Naturopathic doctors (ND) have prescriptive authority in 26 states, but the scope varies. In states like Oregon, Washington, and Arizona, NDs can prescribe most medications including Ozempic. In states like California, ND prescriptive authority is more limited. In states where NDs do not have prescriptive authority, they cannot prescribe Ozempic.

What credentials should I look for in a weight-loss prescriber? Look for an MD, DO, NP, or PA with training or certification in obesity medicine. The American Board of Obesity Medicine (ABOM) certifies physicians in obesity medicine. The Obesity Medicine Association offers certification courses for all provider types. Board certification in family medicine, internal medicine, or endocrinology is also a good indicator of relevant training.

Can my gynecologist prescribe Ozempic for weight loss? Legally, yes. Gynecologists are MDs or DOs with full prescriptive authority. Clinically, most gynecologists would not prescribe Ozempic for weight loss unless they have additional training in obesity medicine. Some gynecologists prescribe GLP-1 agonists for patients with polycystic ovary syndrome (PCOS) and obesity, which is within their scope.

Can a provider in another state prescribe Ozempic for me via telehealth? No. The provider must be licensed in the state where you are physically located at the time of the telehealth visit. A provider licensed only in California cannot prescribe to a patient in Texas, even via telehealth. Some providers hold licenses in multiple states through interstate compacts or individual state licensure.

Sources

1. Walton SM et al. Prioritizing Future Research on Off-Label Prescribing: Results of a Quantitative Evaluation. JAMA Internal Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
4. American Association of Nurse Practitioners. State Practice Environment. 2026.
5. American Academy of Physician Associates. State Laws and Regulations. 2026.
6. Drug Enforcement Administration. Special Registration for Telemedicine, 21 CFR 1306.37. Federal Register. 2024.
7. National Council of State Boards of Nursing. Nurse Licensure Compact. 2026.
8. Interstate Medical Licensure Compact Commission. Participating States. 2026.
9. American Board of Obesity Medicine. Certification Requirements. 2025.
10. Obesity Medicine Association. Clinical Practice Guidelines. 2025.
11. American College of Gastroenterology. GERD Guidelines. 2022.
12. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
13. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. 2024.
14. Federation of State Medical Boards. Telemedicine Policies by State. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly and Company, or any other pharmaceutical manufacturer.